CardioVascular BioTherapeutics, Inc. - Strategic SWOT Analysis Review

Date: April 2, 2014
Pages: 22
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C18AFFC4944EN
Leaflet:

Download PDF Leaflet

CardioVascular BioTherapeutics, Inc. - Strategic SWOT Analysis Review
CardioVascular BioTherapeutics, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
Highlights

Cardiovascular Biotherapeutics, Inc. (CVBT), formerly Cardiovascular Genetic Engineering, is a biopharmaceutical company that focuses on the development and commercialization of novel protein drug candidates for the treatment of cardiovascular diseases. The company focuses its research activities on the development of regenerative therapies, delivery methods and diagnostic techniques with FGF-1 as their active pharmaceutical ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs.

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
SECTION 1 - ABOUT THE COMPANY

CardioVascular BioTherapeutics, Inc. - Key Facts
CardioVascular BioTherapeutics, Inc. - Key Employees
CardioVascular BioTherapeutics, Inc. - Key Employee Biographies
CardioVascular BioTherapeutics, Inc. - Major Products and Services
CardioVascular BioTherapeutics, Inc. - Pharmaceutical Pipeline Products Data
CardioVascular BioTherapeutics, Inc., Pipeline Products by Therapy Area
CardioVascular BioTherapeutics, Inc., Pipeline Products by Development Phase
CardioVascular BioTherapeutics, Inc. - History
CardioVascular BioTherapeutics, Inc. - Company Statement
CardioVascular BioTherapeutics, Inc. - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

CardioVascular BioTherapeutics, Inc. - Business Description
CardioVascular BioTherapeutics, Inc. - SWOT Analysis
SWOT Analysis - Overview
CardioVascular BioTherapeutics, Inc. - Strengths
Strength - Proprietary Technology
Strength - Agreements & Collaboration
CardioVascular BioTherapeutics, Inc. - Weaknesses
Weakness - Reliance on Single Supplier
Weakness - Lack of Product Revenues
CardioVascular BioTherapeutics, Inc. - Opportunities
Opportunity - Future Growth Prospects: Pipeline Programs
Opportunity - Market Potential: Metabolic Disorders
Opportunity - Market Potential: Cardiovascular Diseases (CVD)
CardioVascular BioTherapeutics, Inc. - Threats
Threat - Increasing Competitive Pressures
Threat - Failure of New Product in Clinical Trials
Threat - Stringent Government Regulations
CardioVascular BioTherapeutics, Inc. - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

CardioVascular BioTherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
CardioVascular BioTherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
CardioVascular BioTherapeutics, Inc., Recent Deals Summary

SECTION 4 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

CardioVascular BioTherapeutics, Inc., Key Facts
CardioVascular BioTherapeutics, Inc., Key Employees
CardioVascular BioTherapeutics, Inc., Key Employee Biographies
CardioVascular BioTherapeutics, Inc., Major Products and Services
CardioVascular BioTherapeutics, Inc., Number of Pipeline Products by Therapy Area
CardioVascular BioTherapeutics, Inc., Number of Pipeline Products by Development Stage
CardioVascular BioTherapeutics, Inc., Pipeline Products By Therapy Area and Development Phase
CardioVascular BioTherapeutics, Inc., History
CardioVascular BioTherapeutics, Inc., Key Competitors
CardioVascular BioTherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
CardioVascular BioTherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
CardioVascular BioTherapeutics, Inc., Recent Deals Summary

LIST OF FIGURES

CardioVascular BioTherapeutics, Inc., Pipeline Products by Therapy Area
CardioVascular BioTherapeutics, Inc., Pipeline Products by Development Phase
CardioVascular BioTherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
CardioVascular BioTherapeutics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
Skip to top


Vasamed Inc. - Strategic SWOT Analysis Review US$ 125.00 Jan, 2016 · 20 pages
Genentech, Inc. - Strategic SWOT Analysis Review US$ 125.00 Feb, 2016 · 44 pages

Ask Your Question

CardioVascular BioTherapeutics, Inc. - Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: